Deutsche Bank raised the firm’s price target on Thermo Fisher to $630 from $610 and keeps a Buy rating on the shares. Bioprocessing comprises 8% of Thermo’s total revenue and the company has industry-leading margins and the lowest average portfolio duration, which means it should recover faster than peers, the analyst tells investors in a research note. The firm says Thermo Fisher is the cell culture media leader and offers the largest product portfolio within the peer group across a combination of legacy brands.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMO:
- Thermo Fisher price target raised to $675 from $600 at BofA
- Election 2024: Where To Put Your Money Ahead of the Vote
- Foot Locker trips after earnings, Kohl’s posts Q2 beat: Morning Buzz
- Illumina upgraded, Fiserv initiated: Wall Street’s top analyst calls
- Wells Fargo starts tools and diagnostics group with positive bias